

OCTOBER 2004 DUR BOARD MEETING MINUTES

Date: October 27, 2004

Members Present: Eichler, Nagy, Harrison, Fitzgerald, Sargent, Bradley, Brown, Crichton, Cobb (Telecon)

Others Present: Peterson, Preshinger (Medicaid), Barnhill (Drug PA), Renner (Mental Health Services), Pope, Dawn Daly (First Health), Hunter (DPHHS), Interested members of the public and Representatives of Pharmaceutical manufacturers.

Mark Eichler opened the meeting with an update on meeting procedural changes. The format for PDL discussion has been revised to the following: Presentation of the evidence, public comment, Board discussion. The time limit for individual public comment has been extended to ten minutes, however, at the discretion of the Dept this may change depending on the number of speakers and what is being presented in hopes that not all presenters will use 10 minutes.

Board Minutes: The minutes of the September meeting were approved.

Department update:

Dan Peterson, Pharmacy Program Officer for DPHHS, updated the Board on the following Medicaid issues:

As a result of increased budgetary pressures over the past several years and ongoing budget concerns the Department decided to pursue the Preferred Drug List Project. The Department has filed a rule change and State Plan Amendment to allow us to pursue a Preferred drug list and obtain supplemental rebates from drug manufacturers to obtain the best value in our Medicaid Drug Spend. To obtain the best value the Department has contracted with First Health Services and has elected to participate in the National Medicaid Pooling Initiative. In regards to our State Plan Amendment, the CMS Central Office submitted a list of formal questions which the Dept. Received on Oct 14th. We have answered the questions from CMS and are waiting for approval. CMS has 90 days from the date of our letter to respond. Copies of the questions and the Department's response are available upon request.

On our September 22nd meeting The Department asked that Drug Manufacturers, their representatives or any special interest group representatives not to contact our DUR board members at their places of work or at their homes. To clarify this, sales calls made during the regular course of business do not fall within this request.

Old Business:

Fact trial information will be forwarded to the board.

Preferred Drug List Discussion:

The following drug classes were considered and outcomes determined by review of the evidence, public comment, and then board discussion.

STATINS & CHOLESTEROL ABSORPTION INHIBITORS:

Preferred Drugs – Pravachol & Zetia

Must have as clinical alternatives- Lipitor or Zocor (At least one on the PDL)

Class Effect- All others

COX II's:

Preferred Drug – Celebrex

No change in current Prior Authorization Criteria

ACE INHIBITORS & ACE COMBINATIONS:

Class Effect all drugs

CALCIUM CHANNEL BLOCKERS:

Must have as clinical alternatives - Amlodipine or Felodipine (at least one on the PDL)

Class Effect – All others

CALCIUM CHANNEL BLOCKERS:

Class Effect

BETA-BLOCKERS:

Preferred Drug – Coreg

Class Effect – All others

No grandfathering will be allowed for any of the medications in these classes.

Next meeting is November 17, 2004 at The Wingate Inn Meeting Room in Helena. The December meeting is scheduled to return to the MACO meeting room.

Input was requested from the board about soliciting medical specialist comments about next month's drug classes. The board recommended possibly getting input from an Infectious Disease specialist and/or an Allergist.

Meeting adjourned at 4:30.